Introduction {#Sec1}
============

Compared to adults, a diagnosis of cancer in adolescents and young adults (AYAs) between the ages of 18 and 35 years is rare. Advances in early detection and improvements in cancer treatments have resulted in an overall 5-year survival rate exceeding 80% in AYAs \[[@CR1]\]. While AYAs with cancer face challenges similar to adult cancer patients, those in the heart of their youth experience unique cancer-related challenges in addition to usual age-related developmental tasks. The combination of achieving normal developmental milestones and simultaneously coping with a life-changing diagnosis of cancer frequently leads to psychosocial issues among AYAs with cancer \[[@CR2]\]. Several studies have documented higher levels of distress and lower quality of life (QoL) in AYAs with cancer in comparison with healthy matched peers or adult cancer patients \[[@CR3]--[@CR5]\]. Moreover, treatment-related symptoms (e.g., pain and fatigue) and late effects (e.g., second cancers and cardiovascular disease) can interfere with a healthy body image, establishing social relationships, or attaining levels of autonomy and independence. With the expected further gains in overall survival of AYA cancer, it is important to address persistent disease- and treatment-related symptoms that compromise several domains of QoL.

Cancer-related fatigue (CRF) is one of the most common and distressing symptoms reported by adult and childhood cancer patients both during and after cancer treatment \[[@CR6], [@CR7]\]. The most commonly used definition for CRF is formulated by the National Comprehensive Cancer Network (NCCN) and defines CRF as "*a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity that interferes with usual functioning*" \[[@CR8]\]. The vast majority of studies on the prevalence and severity of CRF have been conducted in adult or childhood cancer patients and only a few studies evaluated fatigue severity in AYAs with cancer. Moreover, the limited AYA-specific studies did not attempt to report on clinically relevant levels of fatigue by using a validated cut-off for severe fatigue \[[@CR4], [@CR9]\].

Knowledge on the prevalence of severe fatigue in AYAs with cancer is important, as we know from studies in adult cancer patients that severe fatigue is associated with more functional impairments, lower QoL, and more distress \[[@CR6], [@CR10]\]. For AYAs with cancer, the impact of severe fatigue might be even more pronounced because it can interrupt developmental milestones such as completing education, finding first or pursuing employment, beginning a romantic relationship, or starting a family. Understanding factors related to severe fatigue among AYAs with cancer will help health care providers identify who is more likely to experience this symptom. In addition, it will help researchers to determine potential factors that could be addressed in interventions targeting fatigue.

The present study determined the prevalence of clinically relevant levels of fatigue in AYAs with cancer using a validated cut-off for severe fatigue and compared the proportion of severely fatigued cases with the proportion of severely fatigued cases in a sample of gender- and age-matched population-based controls. In addition, the impact of severe fatigue on QoL and potential sociodemographic, treatment-related, and psychological correlates of fatigue severity was explored. A cross-sectional approach was used for this study to gather descriptive information about the presence of clinically relevant levels of fatigue among AYAs with cancer.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

Patients aged 18--35 years at cancer diagnosis and who had been seen by at least one of the members of the AYA team of the Radboud university medical center, Nijmegen, The Netherlands, were invited to participate in this study. The AYA team is a dedicated multidisciplinary team including a medical oncologist, clinical nurse specialist, medical psychologist, and social worker. Patients consulting the AYA team receive regular medical care from their own treating specialist (oncologist, surgeon, hematologist, dermatologist, urologist, gynecologist, etc.) and visit the AYA team for age-specific questions and care needs. In general, patients visiting the AYA team represent a group of patients with higher disease severity, diagnosed with relatively advanced stage of disease and undergoing intensive treatments, and reporting more problems with coping. The AYA team does not often see patients with low-stage disease treated solely by surgery, such as in the case of thin melanomas.

To depict the real-life heterogeneous sample of AYAs with cancer visiting the AYA team, AYAs with cancer were included in this first study on the prevalence of severe fatigue regardless of treatment status (during or after treatment), type of treatment (surgery, chemotherapy, radiotherapy, immunotherapy, hormonal therapy or combination), or the number of AYA team visits (some patients only had one introduction talk with one of the members of the team and did not receive specific care thereafter). Inclusion commenced January 2012 and ended March 2016.

Population-based controls {#Sec4}
-------------------------

Population-based controls were derived from a cohort of panel members surveyed by CentERdata, a research institute at Tilburg University collecting data from a sample of more than 2000 Dutch households ([https://www.centerdata.nl/en/](https://www.centerdata.nl/en)). This CentERpanel represents the adult Dutch-speaking population with respect to demographic characteristics. Population-based controls provided self-reported data on age and gender and completed a multi-dimensional fatigue questionnaire (Checklist Individual Strength, see "[Measures](#Sec6){ref-type="sec"}" section). They had no sickness absence in the workplace (0 days) in the month prior to filling in the questionnaires. Further information on the presence of physical or mental health conditions in population-based controls was not available.

Procedure {#Sec5}
---------

Potential study participants were recruited via letters describing the study and inviting patients to participate in the study. Patients willing to participate had to actively opt in to the study by providing written informed consent by email to a member of the AYA team. Participants were then sent a single set of questionnaires by email that could be completed online. The study was deemed exempted from full review and approval by a research ethics committee (CMO Regio Arnhem-Nijmegen, \#2016-2872).

Measures {#Sec6}
--------

AYAs with cancer completed a self-report questionnaire on sociodemographic data (i.e., age, gender, partner status, having children, education level, and employment status). A member of the AYA team (S.K.) extracted clinical data (i.e., cancer diagnosis, disease stage at diagnosis, time since initial cancer diagnosis, type(s) of treatment(s) received, duration of cancer treatment, treatment status at participation, and time since completion of cancer treatment) from patients' medical records. AYAs with cancer completed the following questionnaires, including a multi-dimensional fatigue questionnaire:

### Checklist Individual Strength, subscale fatigue severity (CIS-fatigue) {#FPar1}

The subscale fatigue severity of the CIS consists of eight items scored on a seven-point Likert scale. Total CIS-fatigue scores can range from 8 to 56, with scores greater than 34 indicating clinically relevant levels of fatigue \[[@CR11]\]. The CIS-fatigue has been used in previous studies examining severe fatigue in cancer patients during and after cancer treatment \[[@CR12]--[@CR14]\]. A cut-off was used to group AYAs with cancer into two groups to indicate severely fatigued (≥35) and non-severely fatigued patients (\<35).

### Quality of Life-Cancer Survivor (QoL-CS) {#FPar2}

The QoL-CS consists of 41 items scored on a 10-point Likert scale and was used as a cancer-specific measure of QoL \[[@CR15]\]. The impact of cancer diagnosis and treatment is assessed with four subscales, i.e., physical, social, psychological, and spiritual wellbeing. In addition to the four subscale scores, the total QoL score reflecting the average across all items was used in this study. Higher scores indicated better QoL for all subscales.

### Hospital Anxiety and Depression Scale (HADS) {#FPar3}

The HADS consists of 14 items scored on a four-point Likert scale \[[@CR16]\]. The summed total HADS scores range from 0 to 42 and were used to reflect psychological distress in our sample of AYAs with cancer \[[@CR17]\]. Higher total scores indicate more psychological distress.

### Cancer Worry Scale (CWS) {#FPar4}

The CWS consists of eight items regarding concerns about cancer recurrence or progression of cancer. Items are scored on a four-point Likert scale ranging from "never" to "almost always" \[[@CR18]\]. Total CWS scores range from 8 to 32 and can be used to assess cancer worrying. Higher total scores indicate more fear of cancer recurrence or progression. Patients with a recent recurrence (*n* = 5) or receiving treatment with palliative intent (*n* = 7) did not complete the CWS because the item wording of this measure was irrelevant to them.

Statistical analyses {#Sec7}
--------------------

To compare mean fatigue severity and the prevalence of severe fatigue in AYAs with cancer with population-based controls derived from the sample of CentERdata (*n* = 1923), AYAs with cancer were matched on gender and age (within a range of 0 to 5 years) with 249 population-based controls. Given the relatively low proportion of CentERpanel members within the age range of our study sample, the highest possible ratio for matching AYAs with cancer to controls was 1:3. Precision matching was performed with STATA/SE. All other analyses were performed using SPSS Statistics (version 22.0). Descriptive statistics and frequencies concerning socio-demographic and clinical data were calculated. An independent sample *t* test was used to compare fatigue severity scores between AYAs with cancer and matched population-based controls. We used a chi-square test to compare the proportion of severely fatigued cases in AYAs with cancer and matched population-based controls. Pearson and point-biserial correlations were calculated to examine associations between continuous variables or continuous and dichotomous variables, respectively. The significance level was set at .05. We did not adjust for multiple testing.

Results {#Sec8}
=======

In total, 309 letters requesting participation in the study were sent to AYAs with cancer visiting one of the members of the AYA team. The total sample of 89 participants comprised 57% of those who opted in to the study (*n* = 155) and 29% of all those solicited by mail (*n* = 309). Six participants were excluded, four since they were diagnosed with cancer under the age of 18 years and two because they were aged above 35 years at diagnosis. Table [1](#Tab1){ref-type="table"} displays sociodemographic and disease- and treatment-related characteristics of the final sample of 83 AYAs with cancer stratified by the presence of severe fatigue. Mean age at cancer diagnosis for the total sample was 27.3 years (SD 4.4) and mean time since cancer diagnosis was 2.1 years (SD 2.6). The most common diagnosis was testicular cancer (34%) followed by sarcoma (19%). Disease stage at diagnosis was known and applicable in 67 participants. Of those, 36 (54%) were diagnosed with early stage disease (stages I--II) and 31 (46%) with late-stage disease (stages III--IV). The majority of participants had undergone surgery (*n* = 70, 84%) and chemotherapy (*n* = 72, 87%) but were not on active cancer treatment at the time of study participation (*n* = 61, 73.5%). Mean duration of cancer treatment was 15.8 months (SD 20.6). For the subset of 61 patients not on active cancer treatment at the time of study participation, mean duration since completion of treatment was 17.5 months (SD 30.6).Table 1Characteristics of the study sample stratified by fatigue severityCharacteristicsTotal sample (*n* = 83)Non-severely fatigued patients (*n* = 43)Severely fatigued patients (*n* = 40)Age at cancer diagnosis, mean (SD)27.3 (4.4)26.5 (4.6)28.0 (4.1) 18--25 years\
 26--35 years30 (36%)\
53 (64%)18 (42%)\
25 (58%)12 (30%)\
28 (70%)Age at participation, mean (SD)\
 18--25 years\
 26--35 years\
 \>35 years29.4 (4.7)\
19 (23%)\
58 (70%)\
6 (7%)28.7 (5.0)\
13 (30%)\
27 (63%)\
3 (7%)30.2 (4.4)\
6 (15%)\
31 (77.5%)\
3 (7.5%)Gender Male43 (52%)30 (70%)13 (32.5%) Female40 (48%)13 (30%)27 (67.5%)Partner^a^ Yes\
 No58 (70%)\
24 (29%)32 (74%)\
11 (26%)26 (67%)\
13 (33%)Children^a^ Yes\
 No27 (33%)\
55 (66%)30 (70%)\
13 (30%)25 (64%)\
14 (36%)Highest completed education^a^ Low\
 Intermediate\
 High2 (2%)\
36 (43%)\
44 (53%)0 (0%)\
18 (42%)\
25 (58%)2 (5%)\
18 (46%)\
19 (49%)Employed or studying^a^ Yes\
 No\
 Other53 (64%)\
26 (31%)\
3 (4%)37 (86%)\
4 (9%)\
2 (5%)16 (40%)\
22 (55%)\
1 (2.5%)Cancer diagnosis Testicular cancer\
 Sarcoma\
 Breast cancer\
 Hematological malignancy\
 Gynecological cancer\
 Melanoma\
 Other^b^28 (34%)\
16 (19%)\
10 (12%)\
10 (12%)\
9 (11%)\
3 (4%)\
7 (8%)22 (51%)\
5 (12%)\
4 (9%)\
2 (5%)\
5 (12%)\
2 (5%)\
3 (7%)6 (15%)\
11 (27.5%)\
6 (15%)\
8 (20%)\
4 (10%)\
1 (2.5%)\
4 (10%)Cancer stage at diagnosis Not applicable\
 Stage I\
 Stage II\
 Stage III\
 Stage IV\
 Unknown9 (11%)\
11 (13%)\
25 (30%)\
13 (16%)\
18 (22%)\
7 (8%)3 (7%)\
6 (14%)\
18 (42%)\
3 (7%)\
11 (26%)\
2 (5%)6 (15%)\
5 (12.5%)\
7 (17.5%)\
10 (25%)\
7 (17.5%)\
5 (12.5%)Time since cancer diagnosis, mean (SD) in years2.1 (2.6)2.0 (1.8)2.2 (3.3)Lifetime cancer treatment^c^ Surgery\
 Chemotherapy\
 Radiotherapy\
 Immuno- or targeted therapy\
 Hormone therapy70 (84%)\
72 (87%)\
24 (29%)\
13 (16%)\
7 (8%)38 (88%)\
38 (88%)\
10 (23%)\
5 (12%)\
4 (9%)32 (80%)\
34 (85%)\
14 (35%)\
8 (20%)\
3 (7.5%)Intent of cancer treatment Curative\
 Palliative71 (85.5%)\
12 (14.5%)40 (93%)\
3 (7%)31 (77.5%)\
9 (22.5%)Duration of cancer treatment,\
mean (SD) in months15.8 (20.6)15.0 (22.1)16.7 (19.2)Treatment status at participation No active treatment\
 Active treatment61 (73.5%)\
22 (26.5%)36 (83.7%)\
7 (16.3%)25 (62.5%)\
15 (37.5%)^a^Information was not available for *n* = 1 AYA with cancer^b^Including glioma (*n* = 1), sigmoid carcinoma (*n* = 1), oropharyngeal cancer (*n* = 1), neuroendocrine tumor (*n* = 1), lung cancer (*n* = 1), salivary gland cancer (*n* = 1), and adrenal cancer (*n* = 1)^c^Multiple answers possible

Prevalence of severe fatigue and impact on quality of life {#Sec9}
----------------------------------------------------------

AYAs with cancer reported a significantly higher fatigue severity score than matched population-based controls (31.5, SD 11.8 versus 24.9, SD 10.5, respectively, *p* \< .001). The prevalence of severe fatigue in AYAs with cancer was significantly higher in comparison with matched population-based controls (48%, *n* = 40/83 versus 20%, *n* = 49/249, respectively, *p* \< .001). Severely fatigued AYAs with cancer reported significantly lower scores on all four QoL subscales (i.e., physical, social, psychological, and spiritual well-being) and on total QoL, compared to their non-severely fatigued counterparts (*p* \< .05, see Table [2](#Tab2){ref-type="table"}).Table 2Impact of severe fatigue on quality of life of AYAs with cancerNon-severely fatigued patients (*n* = 43)Severely fatigued patients (*n* = 40)QoL-CSMean (SD)Mean (SD)Mean differenceSig.Physical well-being\
Social well-being\
Psychological well-being\
Spiritual well-being\
Total QoL8.28 (1.21)\
5.41 (1.33)\
6.27 (1.29)\
4.21 (1.16)\
6.12 (0.82)6.57 (1.49)\
4.81 (1.30)\
4.90 (1.59)\
3.29 (1.36)\
4.95 (1.13)−1.71\
−0.60\
−1.37\
−0.92\
−1.17.000\*\*\
.042\*\
.000\*\*\
.001\*\*\
.000\*\*\*Mean difference is significant at the 0.05 level; \*\*Mean difference is significant at the 0.01 level

Sociodemographic, treatment-related, and psychosocial correlates of fatigue severity {#Sec10}
------------------------------------------------------------------------------------

Correlations are listed in Table [3](#Tab3){ref-type="table"}. Higher psychological distress was strongly correlated to fatigue severity (*R* = .55; *p* \< .001). Female gender, being unemployed (not having a job, sick leave or disablement insurance act), higher disease stage (III--IV) at diagnosis, and higher fear of recurrence or progression were moderate correlates (*R*'s 0.30 to 0.50; *p* \< .01). In addition, receiving active treatment at the time of study participation, palliative intent of treatment, and having had radiotherapy were weakly associated with fatigue severity (*R*'s 0.10 to 0.30; *p* \< .05). No significant associations were observed between fatigue severity and the other sociodemographic and disease- and treatment-related variables (see Table [3](#Tab3){ref-type="table"}; *p* \> .05).Table 3Correlates of fatigue severity in AYAs with cancerCorrelation coefficientsNo.Sig.Sociodemographic variables Age at cancer diagnosis\
 Age at participation\
 Gender (male/*female*)\
 Partner status (yes/no)\
 Children (yes/no)\
 Employed or studying (yes/*no*).194\
.185\
.336\
.118\
−.122\
.39483\
83\
83\
82\
82\
79.079\
.093\
.002\*\*\
.291\
.273\
.000\*\*Disease- and treatment-related variables Time since cancer diagnosis\
 Cancer stage at diagnosis (early/*late*)^a^\
 Duration of cancer treatment\
 Cancer treatment at participation (yes/*no*)\
 Time since completion of cancer treatment\
 Intent of cancer treatment (curative/*palliative*)\
 Surgery (yes/no)\
 Chemotherapy (yes/no)\
 Radiotherapy (yes/*no*)\
 Immuno- or targeted therapy (yes/no)\
 Hormone therapy (yes/no).073\
.322\
.087\
−.227\
.060\
.270\
.178\
.115\
−.242\
−.107\
.06483\
67\
81\
83\
61\
83\
83\
83\
83\
83\
83.513\
.008\*\
.439\
.039\*\
.646\
.013\*\
.108\
.302\
.028\*\
.336\
.563Psychological variables Psychological distress (HADS total)\
 Fear of recurrence or progression (CWS total)^b^.553\
.34083\
71.000\*\*\
.004\*\*\*Correlation is significant at the 0.05 level; \*\*Correlation is significant at the 0.01 level.^a^Cancer stage was unknown for *n* = 7 AYAs with cancer and not applicable for *n* = 9 AYAs with cancer^b^CWS was not administered to *n* = 12 AYAs with cancer, because they either had a recurrence (*n* = 5) or received treatment with palliative intent (*n* = 7)

Discussion {#Sec11}
==========

In this study, severe fatigue affected almost half of the AYAs with cancer. The prevalence of severe fatigue in AYAs with cancer was more than twice as high in AYAs with cancer than in gender- and age-matched population-based controls (48 versus 20%). Severe fatigue as assessed with the CIS-fatigue is more prevalent among AYAs with cancer than adult disease-free breast cancer patients 3 years after diagnosis (38%) \[[@CR19]\]. The prevalence among AYAs with cancer corresponds more closely with findings from a study performed in adult cancer patients during cancer treatment with palliative intent (47%) \[[@CR13]\], which is remarkable given the major difference in prognosis between these two patient groups. In our sample, only a minority of the participants (*n* = 12, 14.5%) were classified as being treated with palliative intent at the time of participation. Reasons for the high prevalence of severe fatigue in AYAs with cancer have not been studied. One might postulate that, in contrast to adult cancer patients, the higher prevalence of severe fatigue originates from the unique combination of being diagnosed and treated for cancer and the developmental milestones AYAs are confronted with during adolescence and young adulthood.

Alternatively, the higher prevalence of severe fatigue reported by participants in our study could be the result of selection bias. We recruited AYAs with cancer that consulted a multidisciplinary AYA team. The fact that patients consulted a specialized AYA team most likely indicates that these patients had additional disease and/or treatment-related questions or problems, although not all patients had a need for continued and specific care by the AYA team after the first consultation. The percentage of patients having had chemotherapy as part of AYA cancer treatment was high (87%). This further supports the likelihood of selection bias in our sample and might overestimate disease severity of the entire AYA cancer patient population. Nonetheless, we can conclude that within the subset of AYAs with cancer consulting a multidisciplinary AYA team, the prevalence of severe fatigue is substantial.

Significant differences were found in physical, social, psychological, spiritual, and total QoL for severely fatigued AYAs with cancer in comparison with non-severely fatigued patients, which echoes previous studies reporting on the detrimental effects of severe fatigue in adult cancer patients \[[@CR6], [@CR10]\]. More psychological distress was a strong correlate of fatigue severity in the present study. In addition, more cancer worrying, female gender, and being unemployed were moderately related to fatigue severity. Geue et al. (2014) studied gender-specific differences in quality of life after AYA cancer and found lower QoL for women than men, including higher levels of fatigue \[[@CR20]\]. The finding that more psychological distress and cancer worrying were associated with fatigue severity is in agreement with the impact of fatigue severity on QoL of AYAs with cancer in this study. However, given the cross-sectional design of our study, we cannot draw conclusions on causality. This also limits interpreting the finding that being unemployed was linked to higher fatigue severity, although it may suggest that severely fatigued AYAs with cancer might not be able to find appropriate work. This emphasizes the relevance of further research into this topic.

We only found weak or non-significant links between treatment-related variables and fatigue severity; receiving active treatment at the time of study participation, receiving treatment with palliative intent, and having had radiotherapy were significant but weakly related to fatigue severity. A moderate association was found between late-stage cancer at diagnosis and fatigue severity. In previous studies among adult cancer patients during and after treatment, fatigue appeared to be unrelated to disease-related variables, but the receipt of chemotherapy was associated with fatigue long after treatment \[[@CR21]\]. A recently published review among breast cancer survivors after treatment also reported that survivors treated with chemotherapy were at higher risk for developing severe fatigue, as were those survivors with a higher disease stage at diagnosis \[[@CR22]\]. As mentioned before, a noteworthy proportion of participants (87%) in our sample had been treated with chemotherapy.

The present study has several limitations. The sample size of our study was relatively small and the low participation rate increases the probability of bias by non-response. Unfortunately, small sample sizes are also seen in other studies in which patients of AYA age are asked to participate \[[@CR23], [@CR24]\]. Recruitment for our study took place over a period of 4 years. Additional efforts to increase data collection, such as multiple mailings of questionnaires or follow-up phone calls, were only made in the latter part of the study. Our response rate might have been higher when these efforts were made throughout the entire duration of the study. However, in the AYA HOPE study, fewer than half of the eligible AYAs with cancer responded to questionnaires despite extensive efforts such as multiple mailings, phone calls, and financial incentives \[[@CR25]\]. One way to overcome the low response rate in AYA cancer research might be the use of in-person contact and patient-preferred paper-pencil rather than online surveys as recently suggested by Rosenberg et al. \[[@CR26]\]. Given the low incidence of cancer in AYAs between the ages of 18 to 35 years, recruitment from multiple institutions in an (inter)national AYA network could also aid the collection of larger samples. This would also increase the ability to generalize findings, which is limited in our study since we recruited patients at a single university medical center. While a broad range of potential correlates of fatigue severity was studied, we cannot rule out the involvement of other potentially relevant factors that have not been examined in this study. For example, sleep problems are strongly correlated with higher levels of fatigue in patients with cancer \[[@CR27]\]. In addition, a low level of physical activity and pain are also correlated with cancer-related fatigue \[[@CR28]\]. There is evidence that the effect of sleep problems on fatigue is mediated by pain \[[@CR29]\]. Unfortunately, we did not include validated instruments to assess sleep problems, physical activity, and pain as potential correlates of fatigue severity in our sample, which is a significant limitation of the study. Notwithstanding these limitations, the present study is the first to apply a clinically relevant cut-off for severe fatigue in AYAs with cancer aged between 18 and 35 years at diagnosis.

In conclusion, given the high prevalence and significant impact of severe fatigue on quality of life of AYAs with cancer, health care providers should pay careful attention to this symptom. In particular, female AYAs with cancer, those with more advanced disease at diagnosis, higher levels of psychological distress, and more cancer worrying seem to experience higher levels of fatigue. The longer-term survivorship rates of AYA cancer illustrate the potential longevity of AYAs with cancer. It is therefore important to investigate the course and persistence of severe fatigue in AYAs with cancer in longitudinal, population-based studies. Such studies would also aid the development of age-specific interventions addressing persistent cancer-related fatigue in AYAs with cancer to enable full participation in society throughout survivorship. Although evidence-based interventions for the management of cancer-related fatigue in adult cancer survivors are available and recommended within guidelines issued by the American Society for Clinical Oncology \[[@CR30]\], these interventions have not been tested extensively in AYAs with cancer. Researchers should investigate whether these interventions can also be successfully applied to alleviate persistent cancer-related fatigue, improve QoL, and facilitate participation in society for the understudied population of AYAs with cancer.

The original version of this article was revised: Tables 2 and 3 are corrected.

An erratum to this article is available at <https://doi.org/10.1007/s00520-017-3778-5>.
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